U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H24N2O2
Molecular Weight 348.439
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of ACRIVASTINE

SMILES

Cc1ccc(cc1)/C(=C(/[H])\CN2CCCC2)/c3cccc(/C(/[H])=C(\[H])/C(=O)O)n3

InChI

InChIKey=PWACSDKDOHSSQD-IUTFFREVSA-N
InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+

HIDE SMILES / InChI

Molecular Formula C22H24N2O2
Molecular Weight 348.439
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 2
Optical Activity NONE

Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. It’s used for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. Acrivastine, a structural analog of triprolidine hydrochloride, exhibits H1-antihistaminic activity in isolated tissues, animals, and humans, and has sedative effects in humans. The propionic acid derivative of acrivastine is a metabolite in several animal species (as well as in man) and also exhibits H1-antihistaminic activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SEMPREX-D

Approved Use

SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold.

Launch Date

7.6455359E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
227 ng/mL
8 mg 4 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: PSEUDOEPHEDRINE HYDROCHLORIDE
ACRIVASTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
220 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACRIVASTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
650 μg × h/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACRIVASTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
8 mg 4 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: PSEUDOEPHEDRINE HYDROCHLORIDE
ACRIVASTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
8 mg 4 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: PSEUDOEPHEDRINE HYDROCHLORIDE
ACRIVASTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
24 mg 1 times / day single, oral
Highest studied dose
Dose: 24 mg, 1 times / day
Route: oral
Route: single
Dose: 24 mg, 1 times / day
Sources:
healthy, 21-45 years
n = 18
Health Status: healthy
Age Group: 21-45 years
Sex: F
Population Size: 18
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria.
1989
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Patents

Sample Use Guides

The recommended dosage for adults and adolescents 12 years and older is one capsule administered orally, every 4 to 6 hours four times a day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:24:16 UTC 2021
Edited
by admin
on Sat Jun 26 05:24:16 UTC 2021
Record UNII
A20F9XAI7W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACRIVASTINE
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
2-PROPENOIC ACID, 3-(6-(1-(4-METHYLPHENYL)-3-(1-PYRROLIDINYL)-1-PROPENYL)-2-PYRIDINYL)-, (E,E)-
Common Name English
ACRIVASTINE [WHO-DD]
Common Name English
ACRIVASTINE [MI]
Common Name English
ACRIVASTINE COMPONENT OF SEMPREX-D
Common Name English
BW 825C
Code English
ACRIVASTINE [USAN]
Common Name English
ACRIVASTINE [INN]
Common Name English
ACRIVASTINE [VANDF]
Common Name English
ACRIVASTINE [ORANGE BOOK]
Common Name English
(E)-6-((E)-3-(1-PYRROLIDINYL)-1-P-TOLYLPROPENYL)-2-PYRIDINEACRYLIC ACID
Common Name English
BW-825C
Code English
ACRIVASTINE [MART.]
Common Name English
6-(3-(1-PYRROLIDINYL)-1-P-TOLYLPROPENYL)-2-PYRIDINEACRYLIC ACID
Common Name English
SEMPREX-D COMPONENT ACRIVASTINE
Common Name English
3-(6-(1-(4-METHYLPHENYL)-3-(1-PYRROLIDINYL)-1-PROPENYL)-2-PYRIDINYL)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000000190
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
NDF-RT N0000175587
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
WHO-VATC QR06AX18
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
LIVERTOX 13
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
WHO-ATC R06AX18
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
NCI_THESAURUS C29578
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
Code System Code Type Description
PUBCHEM
5284514
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
NCI_THESAURUS
C47383
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL1224
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
DRUG CENTRAL
82
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
DRUG BANK
DB09488
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
LACTMED
Acrivastine
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
EPA CompTox
87848-99-5
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
RXCUI
19959
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M1388
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY Merck Index
MESH
C043648
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
EVMPD
SUB05252MIG
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
WIKIPEDIA
ACRIVASTINE
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
INN
5548
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
CAS
87848-99-5
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
FDA UNII
A20F9XAI7W
Created by admin on Sat Jun 26 05:24:16 UTC 2021 , Edited by admin on Sat Jun 26 05:24:16 UTC 2021
PRIMARY
Related Record Type Details
INHIBITOR -> TARGET
Related Record Type Details
ACTIVE MOIETY